Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golcadomide in Combination With Rituximab in Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302Phase 2Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Aug 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of golcadomide in follicular lymphoma (FL) (3 arms), sponsored by Celgene Corporation. Primary endpoint: Complete Metabolic Response at 12 months. Started Aug 2024; status: active, not recruiting.
02
Drugs
golcadomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06425302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06425302.